Exelixis | La Marge Brute Sur Les Ventes



Gross Profit On Sales Changement Date
Acadia Pharmaceuticals USD 237.8M 72.86M 2024-12
Agios Pharmaceuticals USD 9.47M 1.29M 2024-12
Amgen USD 5.97B 781M 2024-12
AstraZeneca USD 12.17B 1.06B 2024-12
Bayer EUR 6.01B 1.13B 2024-12
BioMarin Pharmaceutical USD 611.17M 53.89M 2024-12
Bristol-Myers Squibb USD 9.13B 94M 2024-12
Cytokinetics -160545000 81.19M 2024-09
Eisai JPY 170.21B 16.72B 2024-12
Eli Lilly USD 11.13B 1.86B 2024-12
Exelixis USD 546.79M 24.58M 2025-01
Genmab DKK 6.1B 837M 2024-12
Glaxosmithkline GBP 5.6B 94M 2024-12
Incyte USD 1.1B 38.34M 2024-12
Ionis Pharmaceuticals USD 222.75M 90M 2024-12
MacroGenics USD 13.86M 94.98M 2024-12
Merck USD 11.92B 852M 2024-12
Moderna USD 420M 1.14B 2024-12
Neurocrine Biosciences USD 618.4M 4.3M 2024-12
Novartis USD 10.23B 294M 2024-12
Pfizer USD 12.11B 718M 2024-12
Sanofi EUR 5.36B 4.71B 2024-12
Takeda JPY 727.25B 54.48B 2024-12
Ultragenyx Pharmaceutical USD 147.98M 29.51M 2024-12
Xencor -45143000 40.69M 2024-09



Exelixis La Marge Brute Sur Les Ventes - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Apr 2025.